Home
>
US Stocks
>
DAY ONE BIOPHARMACEUTICALS I

DAY ONE BIOPHARMACEUTICALS I (DAWN)

$13.45

+0.15

(+1.13%)▲

Live

Performance

  • $12.65
    $13.64
    $13.45
    downward going graph

    5.95%

    Downside

    Day's Volatility :7.26%

    Upside

    1.39%

    downward going graph
  • $6.03
    $28.35
    $13.45
    downward going graph

    55.17%

    Downside

    52 Weeks Volatility :78.73%

    Upside

    52.56%

    downward going graph

Returns

PeriodDAY ONE BIOPHARMACEUTICALS ISector (Health Care)Index (Russel 2000)
3 Months
-28.42%
0.7%
-6.8%
6 Months
-37.32%
-8.3%
-6.0%
1 Year
102.74%
-1.9%
-4.6%
3 Years
-38.85%
25.3%
25.9%

Highlights

Market Capitalization
978.5M
Book Value
$4.08
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.2
Wall Street Target Price
39.56
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-34.88%
Return On Equity TTM
-56.01%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-165.0M
Diluted Eps TTM
-2.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.48
EPS Estimate Next Year
-2.05
EPS Estimate Current Quarter
-0.59
EPS Estimate Next Quarter
-0.6

Analyst Recommendation

Buy
    82%Buy
    11%Hold
    5%Sell
Based on 17 Wall street analysts offering stock ratings for DAY ONE BIOPHARMACEUTICALS I(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
15
14
Hold
2
2
1
Sell
1
00
00

Analyst Forecast

What analysts predicted

Upside of 194.13%

Current $13.45
Target $39.56

Technicals Summary

Sell

Neutral

Buy

DAY ONE BIOPHARMACEUTICALS I is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
DAY ONE BIOPHARMACEUTICALS I
DAY ONE BIOPHARMACEUTICALS I
-8.09%
-37.32%
102.74%
-38.85%
-38.85%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
DAY ONE BIOPHARMACEUTICALS I
DAY ONE BIOPHARMACEUTICALS I
3.54
NA
NA
-2.48
-0.56
-0.35
0.0
4.08
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
DAY ONE BIOPHARMACEUTICALS I
DAY ONE BIOPHARMACEUTICALS I
Buy
$978.5M
-38.85%
3.54
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • FMR Inc

    12.24%

  • RA Capital Management, LLC

    9.57%

  • Franklin Resources Inc

    4.63%

  • Vanguard Group Inc

    4.26%

  • Canaan Partners XI LLC

    3.46%

  • BlackRock Inc

    3.31%

Company Information

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.

Organization
DAY ONE BIOPHARMACEUTICALS I
Employees
125
CEO
Dr. Jeremy Bender M.B.A., Ph.D.
Industry
Healthcare

Discover More

FAQs